69 Years of Phapros' Contribution to the Development of Indonesia's Pharmaceutical Sector

Jakarta, June 21, 2023 - PT Phapros Tbk, which is part of the State-Owned Pharmaceutical Holding, is celebrating its 69th anniversary this year. Since its establishment on June 21, 1954, the company, which owns the Antimo brand, has achieved various accomplishments in terms of financial performance, contributions to society through the TJSL program, and the production of 500 million units of Blood Enhancing Tablets (TTD).

In addition, Phapros has also successfully carried out various corporate actions, such as listing on the Indonesia Stock Exchange in 2018 and acquiring local pharmaceutical companies in the same year. Phapros' expansion of products to the global market is also part of the company's milestone journey with the stock code PEHA, including in Cambodia and South America.

According to the President Director of PT Phapros Tbk, Hadi Kardoko, the achievements over the past 69 years would not have been possible without the contributions of various parties, including shareholders, investors, employees, the government, trading partners, research institutions and universities, the parent company Kimia Farma, and the general public.

"Since its establishment in 1954, what we have achieved so far is something that all parties involved in Phapros' journey can be proud of. In 2022, Phapros produced 500 million units of blood-enhancing tablets. This achievement is also proof of Phapros' commitment to supporting the government in reducing the number of children with stunted growth," he said during the celebration of PT Phapros Tbk's 69th anniversary.

Hadi stated that throughout Phapros' history, the company has always produced research-based medicines and medical devices that are needed by the community and safe to use. Several renowned institutions in the country have collaborated with Phapros, such as BRIN, Gajah Mada University, RSUD dr. Soetomo, and other domestic research and educational institutions.

"We are committed to research downstream. Some of the focuses we have implemented include bone fillers in powder form that can be used for dental implants, early detection devices for cervical cancer, nasopharyngeal cancer detection devices, and others."

"This June, our subsidiary, Lucas Djaja Group, exported Fluza tablets to Myanmar. This product has been regularly exported there since 1998, and this year we will release 12 containers," Hadi added.

On the other hand, Nailul Huda, a researcher at INDEF, stated that the pharmaceutical industry has the opportunity to continue growing post-pandemic, making it a recommendation for investment portfolios for investors. "For those investing for the long term, not short-term traders, I believe that pharmaceutical stocks can still be a reliable investment," he added.